ArticleFrontiers in oncology2025
Case Report: Transforming small cell lung cancer: two cases report and literature review.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transformation of non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC) is a relatively rare event with an incidence of about 3%-14%. Due to the poor treatment outcomes and prognosis associated with this transformation, understanding its underlying mechanisms is crucial for improving the diagnosis, management, and prognosis of transformed small cell lung cancer (T-SCLC). In this paper, we present two cases of T-SCLC and review the molecular mechanisms, clinical features, and treatment strategies post-transformation. We emphasize the importance of considering pathological transformation in cases of resistance to NSCLC treatment, monitoring changes in tumor markers, and conducting a re-biopsy. Finally, we propose effective treatment measures for managing T-SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.